Literature DB >> 17061238

Successful management of melanocytoma-associated choroidal neovascularization with photodynamic therapy.

K V Chalam1, S K Gupta, G Y Shah, S Agarwal.   

Abstract

PURPOSE: To report the efficacy of photodynamic therapy in treatment of choroidal neovascular membrane (CNV) associated with melanocytoma of the optic disc.
METHODS: A middle-aged man with visual acuity of 20/200 in right eye was treated with photodynamic therapy for juxtafoveal classic CNV overlying the papillomacular bundle. CNV was secondary to ocular melanocytoma, a rare event.
RESULTS: At the 6-month follow-up, a scarred CNV with final visual acuity of 20/30 was noted clinically and angiographically. Tomography revealed high reflective scar tissue with flat macula and microperimetry showed restoration of retinal sensitivity over the papillomacular bundle.
CONCLUSIONS: Photodynamic therapy effectively resolved CNV that involved papillomacular bundle (secondary to melanocytoma) and restored retinal function in papillomacular bundle.

Entities:  

Mesh:

Year:  2006        PMID: 17061238

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  3 in total

1.  Bevacizumab for the treatment of a complicated posterior melanocytoma.

Authors:  Julio A Urrets-Zavalia; Nicolas Crim; Evangelina Esposito; Leandro Correa; M Eugenia Gonzalez-Castellanos; Dana Martinez
Journal:  Clin Ophthalmol       Date:  2015-03-06

2.  Management of Choroidal Neovascularization Associated with Optic Disc Melanocytoma with Intravitreal Aflibercept: A Case Report and Review of the Literature.

Authors:  Hany S Hamza; Magdy Moussa; Abdelrahman M Elhusseiny
Journal:  Case Rep Ophthalmol Med       Date:  2019-08-07

3.  Optic disk melanocytoma associated with polypoidal choroidal vasculopathy lesions, after combination treatment of photodynamic therapy and intavitreal aflibercept (Eylea), a case report.

Authors:  Alexandros Rouvas; Nikolaos S Gouliopoulos; Marilita M Moschos; Panagiotis Theodossiadis
Journal:  BMC Ophthalmol       Date:  2018-10-12       Impact factor: 2.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.